GlassScriptPhysician profile
Constance C Dabezies
NPI 1164425310
$1,119.34
in general payments reported to CMS, 2019-2025
15 companies · $421 in 2025
The $421 reported for 2025 was more than what 76% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $17.98 · 2023: $432 · 2024: $248 · 2025: $421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $922 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $922.11 |
| Education | $179.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $621.66 | 2023-2025 | Veozah |
| Mayne Pharma Commercial LLC | $164.60 | 2025 | |
| Exeltis, USA INC. | $53.78 | 2023-2025 | Slynd |
| Sumitomo Pharma America, INC. | $36.40 | 2023-2025 | Myfembree, Gemtesa |
| Baxter Healthcare | $35.49 | 2024-2025 | Perclot |
| Astellas Pharma Global Development | $32.84 | 2023-2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $30.96 | 2023-2024 | |
| Sage Therapeutics, LLC | $24.03 | 2025 | Zulresso |
| Coopersurgical, INC. | $19.11 | 2023 | Mara Console |
| Evofem Biosciences, INC. | $18.65 | 2024 | |
| Organon LLC | $17.98 | 2022 | |
| Sanofi Pasteur INC. | $17.30 | 2025 | |
| Meditrina | $16.89 | 2023 | |
| Dexcom, INC. | $16.29 | 2023 | Dexcom G6 Transmitter |
| Millicent US INC | $13.36 | 2024 | Femring, Intrarosa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Constance Dabezies listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.